Primary CNS Lymphoma: Diagnosis, Treatment and Prognosis — Overview, Diagnosis & Treatment Options | MyMedicPlus

Primary CNS lymphoma (PCNSL) is an aggressive extranodal non-Hodgkin lymphoma confined exclusively to the brain, spinal cord, eyes (vitreoretinal lymphoma, occurring in approximately 15-25% of PCNSL), leptomeninges, or cranial nerves — without systemic involvement at initial diagnosis. Approximately 1,500 new cases are diagnosed annually in the United States; the incidence rises steeply after age 60 in immunocompetent patients and in any age group with immunosuppression. Diffuse large B-cell lymphoma (DLBCL), of the non-germinal center B-cell (non-GCB) subtype, accounts for approximately 95% of PCNSL in immunocompetent hosts. Immunosuppression-related PCNSL (HIV/AIDS, post-transplant) is typically Epstein-Barr virus-positive and may differ in behavior and prognosis. The blood-brain barrier limits penetration of most systemic chemotherapy agents into the CNS, which is why PCNSL requires specialized treatment regimens featuring high-dose methotrexate rather than standard CHOP-based lymphoma protocols.

Immunosuppression is the primary risk factor for PCNSL. HIV/AIDS — particularly before effective antiretroviral therapy — dramatically increased PCNSL risk, typically EBV-driven. Solid organ transplant recipients receiving calcineurin inhibitors and other immunosuppressive agents have a 10-12 fold elevated risk. Congenital immunodeficiency syndromes (Wiskott-Aldrich, severe combined immunodeficiency) also predispose. In immunocompetent patients, PCNSL arises from B-cells that have trafficked into the CNS sanctuary site. Molecular pathogenesis involves constitutive activation of B-cell receptor (BCR) signaling and Toll-like receptor (TLR) pathways: MYD88 L265P mutations (in approximately 80% of PCNSL) and CD79B mutations (approximately 50%) are the dominant oncogenic drivers, analogous to ABC-subtype DLBCL. These mutations activate NF-kappaB signaling, promoting B-cell survival and proliferation. Peak incidence in immunocompetent patients occurs in the sixth and seventh decades with a slight male predominance.

PCNSL typically presents with subacutely progressive neurological deficits developing over days to several weeks — more rapidly than primary brain tumors but more gradually than stroke. Focal neurological deficits are the most common presenting feature, including hemiparesis, aphasia, cerebellar ataxia, and cranial nerve palsies, reflecting the periventricular and deep white matter tropism of PCNSL. Cognitive changes, personality changes, and behavioral disturbances are particularly common and may be the predominant or initial manifestation, frequently causing an initial misdiagnosis of behavioral or psychiatric disorder. Raised intracranial pressure causes headache, nausea, and vomiting. Seizures occur in approximately 10-15% at presentation. Ocular symptoms — painless visual changes, floaters, or blurred vision — arise in patients with vitreoretinal lymphoma involvement (occurring in approximately 15-25%). Leptomeningeal involvement (approximately 40%) may produce radicular pain, cranial neuropathies, or cauda equina syndrome.

MRI brain with gadolinium is the key imaging modality: PCNSL characteristically appears as a homogeneously enhancing periventricular or deep white matter mass (sometimes multiple) with surrounding edema. Unlike glioma, PCNSL typically shows dense homogeneous enhancement without necrosis and marked diffusion restriction on DWI sequences due to high cellularity. CSF analysis (lumbar puncture, when safe with respect to ICP) includes cytology and flow cytometry for malignant lymphocytes, cell count, protein, glucose, and IL-10 measurement (elevated IL-10 is highly specific for PCNSL). Slit-lamp examination with vitreous biopsy when needed detects vitreoretinal lymphoma. Stereotactic brain biopsy is the cornerstone of tissue diagnosis — corticosteroids must be withheld before biopsy to avoid false-negative results from glucocorticoid-induced lympholysis. MYD88 L265P and CD79B testing on biopsy or CSF cell-free DNA. Systemic staging (CT chest/abdomen/pelvis, bone marrow biopsy, and testicular ultrasound in men) excludes systemic DLBCL with secondary CNS involvement. HIV serology and ophthalmology assessment are mandatory.

Treatment of PCNSL is guided by patient age, performance status, and renal function (methotrexate clearance). The established induction regimen is high-dose methotrexate (HD-MTX, 3-3.5 g/m2 IV every 2-3 weeks) combined with rituximab (anti-CD20) as the cornerstone platform. The MATRix regimen (methotrexate-cytarabine-thiotepa-rituximab, IELSG32 trial) is the highest-intensity widely adopted induction, achieving CR of approximately 49% but requiring intensive supportive care. Alternatively, CALGB 50202 (rituximab-HD-MTX-temozolomide followed by etoposide-cytarabine) is used at many centers. After achieving CR or near-CR, consolidation is standard: for fit patients under 65-70 years, thiotepa-based high-dose chemotherapy followed by autologous SCT (IELSG32 and PRECIS trial data) is preferred over whole-brain radiotherapy (WBRT) due to superior neurocognitive profile. WBRT (23.4-36 Gy) as consolidation carries significant risk of delayed neurotoxicity (particularly dementia and gait disturbance) in patients over 60 and is reserved for transplant-ineligible patients or as salvage. Maintenance rituximab or temozolomide is used in some protocols. For relapsed PCNSL: HD-MTX rechallenge if initially responsive; ibrutinib (BTK inhibitor, active against MYD88-mutated PCNSL); lenalidomide; tisagenlecleucel (CD19 CAR-T, under investigation).

In HIV-infected individuals, effective combination antiretroviral therapy (cART) maintains CD4 counts above 200 cells/mcL and dramatically reduces the risk of EBV-driven PCNSL, which predominantly affects severely immunocompromised patients. Solid organ transplant recipients should be maintained on the lowest effective dose of immunosuppression. Primary prophylaxis against Epstein-Barr virus reactivation with anti-herpesvirus agents may have a theoretical protective role in transplant recipients but is not standard practice. No preventive strategies exist for sporadic immunocompetent PCNSL, which is not associated with known environmental exposures or behavioral risk factors. Population-level screening is not recommended. HIV testing should be offered to all patients with PCNSL as part of the diagnostic evaluation, as antiretroviral therapy alongside lymphoma treatment may improve outcomes in HIV-positive patients.

Any person — particularly those over age 60 or with known immunosuppression — who develops rapidly progressive personality change, cognitive decline, or new focal neurological deficits (weakness, speech difficulty, visual changes) over days to weeks requires urgent neurological evaluation and brain MRI with gadolinium. The key diagnostic clue for PCNSL is the combination of periventricular enhancing lesion on MRI and rapid neurological progression not explained by a clearly vascular or infectious cause. HIV-infected individuals with CD4 counts below 50 cells/mcL who develop neurological symptoms must be evaluated urgently for PCNSL as well as for toxoplasmic encephalitis. Any patient on chronic immunosuppression (transplant, autoimmune disease, chemotherapy) with new neurological changes needs same-day MRI. Critically, corticosteroids must not be given empirically before neurology or neurosurgery consultation, as they can render subsequent diagnostic biopsy non-informative — always biopsy before steroid treatment for suspected PCNSL.

With HD-MTX-based induction and autologous SCT consolidation in fit patients under 65: median OS approximately 5-10 years; 5-year OS approximately 40-50%. Older or transplant-ineligible patients with WBRT consolidation: median OS approximately 3-4 years with significant neurotoxicity risk. HIV-positive PCNSL: prognosis depends heavily on antiretroviral response. MSKCC Prognostic Score guides prognosis based on age, performance status, and CSF protein. The prognosis for Primary CNS Lymphoma: Diagnosis, Treatment and Prognosis varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.